Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd.

Mol Cancer Res. 2018 Mar 9. doi: 10.1158/1541-7786.MCR-17-0594. [Epub ahead of print]

PMID:
29523763
2.

High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women With Low-Grade Cervical Cytology.

Daily LR, Erickson BK, Pasko DN, Straughn JM Jr, Huh WK, Leath CA 3rd.

J Low Genit Tract Dis. 2018 Feb 23. doi: 10.1097/LGT.0000000000000381. [Epub ahead of print]

PMID:
29474240
3.

The Evolution of and Evidence for Opportunistic Salpingectomy.

Dilley SE, Straughn JM Jr, Leath CA 3rd.

Obstet Gynecol. 2017 Oct;130(4):814-824. doi: 10.1097/AOG.0000000000002243. Review.

PMID:
28885426
4.

The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis.

Turner TB, Dilley SE, Smith HJ, Huh WK, Modesitt SC, Rose SL, Rice LW, Fowler JM, Straughn JM Jr.

Gynecol Oncol. 2017 Sep;146(3):642-646. doi: 10.1016/j.ygyno.2017.06.026. Epub 2017 Jun 24.

PMID:
28655413
5.

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

Turner TB, Meza-Perez S, Londoño A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM Jr, Buchsbaum DJ, Randall TD, Arend RC.

Oncotarget. 2017 Jul 4;8(27):44159-44170. doi: 10.18632/oncotarget.17395.

6.

Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.

Smith HJ, Straughn JM, Buchsbaum DJ, Arend RC.

Gynecol Oncol Rep. 2017 Mar 21;20:81-86. doi: 10.1016/j.gore.2017.03.007. eCollection 2017 May. Review.

7.

Does Obesity Affect Pathologic Agreement of Initial and Final Tumor Grade of Disease in Endometrial Cancer Patients?

Daily LR, Boone JD, Machemehl HC, Thomas ED, McGwin G Jr, Straughn JM Jr, Leath CA 3rd.

Int J Gynecol Cancer. 2017 May;27(4):714-719. doi: 10.1097/IGC.0000000000000935.

PMID:
28333843
8.

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM.

Am J Clin Oncol. 2016 Nov 30. [Epub ahead of print]

PMID:
27906723
9.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466.

10.

Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?

Barrington DA, Dilley SE, Landers EE, Thomas ED, Boone JD, Straughn JM Jr, McGwin G Jr, Leath CA 3rd.

Gynecol Oncol. 2016 Dec;143(3):617-621. doi: 10.1016/j.ygyno.2016.10.004. Epub 2016 Oct 6.

11.

Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service.

Smith HJ, Pasko DN, Haygood CLW, Boone JD, Harper LM, Straughn JM Jr.

Gynecol Oncol. 2016 Oct;143(1):105-108. doi: 10.1016/j.ygyno.2016.08.153. Epub 2016 Aug 6.

PMID:
27507186
12.

Ovarian cancer and the immune system - The role of targeted therapies.

Turner TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, Arend RC.

Gynecol Oncol. 2016 Aug;142(2):349-56. doi: 10.1016/j.ygyno.2016.05.007. Epub 2016 May 23. Review.

PMID:
27174875
13.

Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.

Becker DA, Thomas ED, Gilbert AL, Boone JD, Straughn JM Jr, Huh WK, Bevis KS, Leath CA 3rd, Alvarez RD.

Gynecol Oncol. 2016 Jul;142(1):25-29. doi: 10.1016/j.ygyno.2016.04.539. Epub 2016 May 10.

PMID:
27130405
14.

Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.

Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G Jr, Gangrade A, Straughn JM Jr, Buchsbaum DJ.

Lab Invest. 2016 Feb;96(2):249-59. doi: 10.1038/labinvest.2015.150. Epub 2015 Dec 14.

15.

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

Smith HJ, Walters Haygood CL, Arend RC, Leath CA 3rd, Straughn JM Jr.

Gynecol Oncol. 2015 Oct;139(1):59-62. doi: 10.1016/j.ygyno.2015.08.013. Epub 2015 Aug 22.

PMID:
26303225
16.

Niclosamide Analogs for Treatment of Ovarian Cancer.

Walters Haygood CL, Arend RC, Gangrade A, Chettiar S, Regan N, Hassmann CJ 2nd, Li PK, Hidalgo B, Straughn JM Jr, Buchsbaum DJ.

Int J Gynecol Cancer. 2015 Oct;25(8):1377-85. doi: 10.1097/IGC.0000000000000506.

PMID:
26186072
17.

Ovarian and cervical cancer patient derived xenografts: The past, present, and future.

Boone JD, Dobbin ZC, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2015 Aug;138(2):486-91. doi: 10.1016/j.ygyno.2015.05.022. Epub 2015 May 27. Review.

PMID:
26026736
18.

Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project.

Shah MM, Leath CA 3rd, Daily LR, McGwin G Jr, Estes JM, Alvarez RD, Straughn JM Jr.

Int J Gynecol Cancer. 2015 Jun;25(5):798-801. doi: 10.1097/IGC.0000000000000433.

19.

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.

Cohn DE, Barnett JC, Wenzel L, Monk BJ, Burger RA, Straughn JM Jr, Myers ER, Havrilesky LJ.

Gynecol Oncol. 2015 Feb;136(2):293-9. doi: 10.1016/j.ygyno.2014.10.020. Epub 2014 Oct 23.

20.

Outcomes of gynecologic oncology patients undergoing gastrografin small bowel follow-through studies.

Walters CL, Sutton AL, Huddleston-Colburn MK, Whitworth JM, Schneider KE, Straughn JM Jr.

J Reprod Med. 2014 Sep-Oct;59(9-10):476-80.

PMID:
25330690
21.

Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

Walters Haygood CL, Arend RC, Straughn JM, Buchsbaum DJ.

World J Stem Cells. 2014 Sep 26;6(4):441-7. doi: 10.4252/wjsc.v6.i4.441. Review.

22.

Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer.

Erickson BK, Divine LM, Leath CA 3rd, Straughn JM Jr.

Int J Gynecol Cancer. 2014 Oct;24(8):1480-5. doi: 10.1097/IGC.0000000000000222.

PMID:
25188883
23.

Outcomes of gynecologic oncology patients undergoing robotic-assisted laparoscopic procedures in a university setting.

Walters Haygood CL, Fauci JM, Huddleston-Colburn MK, Huh WK, Straughn JM.

J Robot Surg. 2014 Sep;8(3):207-11. doi: 10.1007/s11701-014-0452-5. Epub 2014 Mar 4.

PMID:
27637679
24.

Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.

Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P, Morgan D, Fan J, Straughn JM Jr.

J Nucl Med. 2014 Oct;55(10):1636-42. doi: 10.2967/jnumed.114.143842. Epub 2014 Aug 25.

25.

Validation of a venous thromboembolism risk assessment model in gynecologic oncology.

Stroud W, Whitworth JM, Miklic M, Schneider KE, Finan MA, Scalici J, Reed E, Bazzett-Matabele L, Straughn JM Jr, Rocconi RP.

Gynecol Oncol. 2014 Jul;134(1):160-3. doi: 10.1016/j.ygyno.2014.04.051. Epub 2014 May 4.

PMID:
24796634
26.

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ.

Gynecol Oncol. 2014 Jul;134(1):112-20. doi: 10.1016/j.ygyno.2014.04.005. Epub 2014 Apr 13.

PMID:
24736023
27.
28.

Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.

Erickson BK, Martin JY, Shah MM, Straughn JM Jr, Leath CA 3rd.

Gynecol Oncol. 2014 May;133(2):142-6. doi: 10.1016/j.ygyno.2014.02.006. Epub 2014 Feb 8.

PMID:
24517876
29.

Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients.

Boone JD, Kim KH, Marques M, Straughn JM.

Gynecol Oncol. 2014 Jan;132(1):227-30.

PMID:
24512847
30.

Constructing a Novel Simple LEEP Training Model.

Walters CL, Whitworth JM, Tyra SL, Walsh-Covarrubias JB, Straughn JM Jr.

J Grad Med Educ. 2013 Jun;5(2):320-2. doi: 10.4300/JGME-D-12-00061.1.

31.

Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.

Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM Jr, Landen CN, Ferrone S, Buchsbaum DJ.

Gynecol Oncol. 2014 Jan;132(1):203-10. doi: 10.1016/j.ygyno.2013.10.038. Epub 2013 Nov 9.

PMID:
24216048
32.

The Wnt/β-catenin pathway in ovarian cancer: a review.

Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2013 Dec;131(3):772-9. doi: 10.1016/j.ygyno.2013.09.034. Epub 2013 Oct 11. Review.

PMID:
24125749
33.

Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women.

Leath CA 3rd, Bevis KS, Numnum TM, Ramsey PS, Huh WK, Straughn JM Jr.

J Reprod Med. 2013 Jul-Aug;58(7-8):279-84.

PMID:
23947076
34.
35.

Perioperative morbidity and mortality in octogenarians with ovarian cancer.

Walters CL, Schneider KE, Whitworth JM, Fauci JM, Smith HJ, Barnes MN, Straughn JM.

Int J Gynecol Cancer. 2013 Jul;23(6):1006-9. doi: 10.1097/IGC.0b013e3182980fac.

PMID:
23714708
36.

Screening behaviors and cultural barriers in women with newly diagnosed cervical cancer.

Erickson BK, Zhang B, Straughn JM Jr.

J Low Genit Tract Dis. 2013 Oct;17(4):425-9. doi: 10.1097/LGT.0b013e3182818e31.

PMID:
23595038
37.

Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.

Kerr EH, Frederick PJ, Egger ME, Stockard CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE, Straughn JM, Buchsbaum DJ, Grizzle WE, McNally LR.

Ann Surg Oncol. 2013 Sep;20(9):3059-65. doi: 10.1245/s10434-013-2878-9. Epub 2013 Mar 24.

PMID:
23525731
38.

Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials.

Leath CA 3rd, Straughn JM Jr.

Gynecol Oncol. 2013 Apr;129(1):251-7. doi: 10.1016/j.ygyno.2012.12.035. Epub 2012 Dec 30. Review.

PMID:
23280089
39.

Is selective lymphadenectomy more cost-effective than routine lymphadenectomy in patients with endometrial cancer?

Clements AE, Tierney BJ, Cohn DE, Straughn JM Jr.

Gynecol Oncol. 2013 Feb;128(2):166-70. doi: 10.1016/j.ygyno.2012.10.007. Epub 2012 Oct 16.

PMID:
23078763
40.

A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.

Fauci JM, Straughn JM Jr, Ferrone S, Buchsbaum DJ.

Gynecol Oncol. 2012 Nov;127(2):420-5. doi: 10.1016/j.ygyno.2012.08.017. Epub 2012 Aug 19. Review.

PMID:
22910694
41.

The utilization of palliative care in gynecologic oncology patients near the end of life.

Fauci J, Schneider K, Walters C, Boone J, Whitworth J, Killian E, Straughn JM Jr.

Gynecol Oncol. 2012 Oct;127(1):175-9. doi: 10.1016/j.ygyno.2012.06.025. Epub 2012 Jun 24.

PMID:
22735789
42.

Management of complex pelvic masses using a multivariate index assay: a decision analysis.

Kim KH, Zsebik GN, Straughn JM Jr, Landen CN Jr.

Gynecol Oncol. 2012 Sep;126(3):364-8. doi: 10.1016/j.ygyno.2012.05.027. Epub 2012 May 30.

43.

The core competencies of James Marion Sims, MD.

Straughn JM Jr, Gandy RE, Rodning CB.

Ann Surg. 2012 Jul;256(1):193-202. doi: 10.1097/SLA.0b013e318249ce3b.

PMID:
22514000
44.

Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy.

Ziebarth AJ, Smith H, Killian ME, Nguyen NA, Durst JK, Subramaniam A, Kim KH, Leath CA 3rd, Straughn JM Jr, Alvarez RD.

Gynecol Oncol. 2012 Jul;126(1):69-72. doi: 10.1016/j.ygyno.2012.03.046. Epub 2012 Apr 5.

PMID:
22484400
45.

Morbidity and mortality conference in obstetrics and gynecology: a tool for addressing the 6 core competencies.

Bevis KS, Straughn JM Jr, Kendrick JE, Walsh-Covarrubias J, Kilgore LC.

J Grad Med Educ. 2011 Mar;3(1):100-3. doi: 10.4300/JGME-D-10-00093.1.

46.

Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion.

Whitworth JM, Schneider KE, Fauci JM, Bryant AS, Cerfolio RJ, Straughn JM Jr.

Gynecol Oncol. 2012 Jun;125(3):646-8. doi: 10.1016/j.ygyno.2012.02.029. Epub 2012 Feb 24.

PMID:
22370597
47.

The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.

Whitworth JM, Londoño-Joshi AI, Sellers JC, Oliver PJ, Muccio DD, Atigadda VR, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2012 Apr;125(1):226-30. doi: 10.1016/j.ygyno.2011.12.425. Epub 2011 Dec 9.

48.

The use of retinoids in ovarian cancer: a review of the literature.

Whitworth JM, Straughn JM Jr, Atigadda VR, Muccio DD, Buchsbaum DJ.

Int J Gynecol Cancer. 2012 Feb;22(2):191-8. doi: 10.1097/IGC.0b013e318236a2ec. Review.

PMID:
22146768
49.

Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy: does preoperative anticoagulation matter?

Whitworth JM, Schneider KE, Frederick PJ, Finan MA, Reed E, Fauci JM, Straughn JM Jr, Rocconi RP.

Int J Gynecol Cancer. 2011 Aug;21(6):1131-4. doi: 10.1097/IGC.0b013e31821dc9f0.

PMID:
21792016
50.

Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.

Subramaniam A, Kim KH, Bryant SA, Kimball KJ, Huh WK, Straughn JM, Estes JM, Alvarez RD.

Gynecol Oncol. 2011 Oct;123(1):54-7. doi: 10.1016/j.ygyno.2011.06.012. Epub 2011 Jul 13.

PMID:
21742372

Supplemental Content

Loading ...
Support Center